» Articles » PMID: 33342313

How Do Routine Laboratory Tests Change in Coronavirus Disease 2019?

Overview
Publisher Informa Healthcare
Specialty Science
Date 2020 Dec 21
PMID 33342313
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

How the routine laboratory tests change in terms of coronavirus disease 2019 (COVID-19) was retrospectively analyzed in a large group of patients. Biochemical, hematological and inflammatory variables of a totaly 555 ( = 532 in non-intensive care unit (non-ICU),  = 23 in ICU) patients diagnosed with COVID-19 were analyzed accessing them through the laboratory information system. White blood cell (WBC), neutrophil (NEU), platelet large cell ratio, neutrophil to lymphocyte ratio (NLR), derived NLR (d-NLR), aspartate aminotransferase, urea, creatine kinase (CK) myocardial band (CK-MB), procalcitonin (PCT) values were high whereas lymphocyte (LYM), eosinophil, red blood cells (RBC), hemoglobin, lymphocyte to monocyte ratio, estimated glomerular filtration rate values were low in the ICU group when compared with non-ICU. WBC, NEU, red cell distribution width, alanine transaminase, creatinine, urea, CK-MB, CK, direct bilirubin, lactate dehydrogenase, glucose, C-reactive protein, erythrocyte sedimentation rate, ferritin, D-dimer, PCT and international normalized ratio values increased while RBC, hemoglobin, hematocrit, mean corpuscular volume and total bilirubin values decreased in a significant proportion of patients in both groups based on the normal reference ranges. LYM count was found to be low in a significant number of patients (57.5%) especially in the ICU group and as an important risk factor and diagnostic parameter on admission to ICU (OR: 125, AUC: 0.74). Routine laboratory tests provide important information in terms of both diagnosis and severity of COVID-19. Lymphopenia is a condition that should be monitored which indicates the severity of the disease.

Citing Articles

The external validity of machine learning-based prediction scores from hematological parameters of COVID-19: A study using hospital records from Brazil, Italy, and Western Europe.

Safdari A, Keshav C, Mody D, Verma K, Kaushal U, Burra V PLoS One. 2025; 20(2):e0316467.

PMID: 39903736 PMC: 11793750. DOI: 10.1371/journal.pone.0316467.


Development of Biomarkers and Prognosis Model of Mortality Risk in Patients with COVID-19.

Zhang Z, Tang L, Guo Y, Guo X, Pan Z, Ji X J Inflamm Res. 2024; 17:2445-2457.

PMID: 38681069 PMC: 11048291. DOI: 10.2147/JIR.S449497.


Presepsin as a prognostic biomarker in COVID-19 patients: combining clinical scoring systems and laboratory inflammatory markers for outcome prediction.

Wu Z, Geng N, Liu Z, Pan W, Zhu Y, Shan J Virol J. 2024; 21(1):96.

PMID: 38671532 PMC: 11046891. DOI: 10.1186/s12985-024-02367-1.


Association Between Hemoglobin-Albumin-Lymphocyte-Platelet Index and Mortality in Hospitalized COVID-19 Omicron BA.2 Infected Patients.

Wu W, Lu W, Hong D, Yu X, Xiong L Infect Drug Resist. 2024; 17:1467-1476.

PMID: 38628242 PMC: 11020245. DOI: 10.2147/IDR.S451613.


Association of Coagulopathy and Inflammatory Biomarkers with Severity in SARS-CoV-2-Infected Individuals of the Al-Qunfudhah Region of Saudi Arabia.

Izhari M, Hadadi M, Alharbi R, Gosady A, Sindi A, Dardari D Healthcare (Basel). 2024; 12(7).

PMID: 38610151 PMC: 11012004. DOI: 10.3390/healthcare12070729.